Managing Ocular Side Effects in ELAHERE Treatment

In this episode, Dr. Kristen Lamoreau, OD, delves into the critical role eye care professionals play in managing ocular adverse events for patients undergoing treatment with ELAHERE, the first and only antibody-drug conjugate targeting folate receptor alpha (FRα). As a groundbreaking treatment for certain types of resistant ovarian cancer, ELAHERE is associated with ocular toxicities, necessitating a collaborative approach between eye care providers and oncology teams.